Sang­amo claims a ma­jor mile­stone in gene edit­ing, treat­ing first pa­tient with its zinc fin­ger nu­cle­ase tech

While the lead­ing CRISPR biotechs have been fo­cused on a long, slow windup to their first hu­man stud­ies, one of the orig­i­nal play­ers in the gene edit­ing field has scored boast­ing rights for a first-in-hu­man ex­per­i­ment.

Sang­amo Ther­a­peu­tics $SG­MO has treat­ed its first pa­tient in a Phase I/II tri­al for a rare dis­ease called Hunter syn­drome, or mu­copolysac­cha­ri­do­sis type II — MPS II. Physi­cians tar­get­ed the liv­er with SB-913, which us­es Sang­amo’s zinc fin­ger nu­cle­ase tech de­liv­ered via AAV cells with a cor­rec­tive gene. The ZFNs snip the tar­get­ed liv­er cells to in­sert the cor­rec­tive gene at a spec­i­fied point.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.